**3. Use and impact of generics**

Generic medicines are increasingly being used in most countries across the world. In the US, 9 out of 10 prescriptions are said to have a generic drug [1]. In the European Union (EU), about 20–80% prescriptions are filled with generics [11]. However, lower utilization of generics is reported in the lesser developed countries [12]. Not all generic medicines are available in all countries. Both generics and biosimilars are widely used in hematological malignancies. Examples include lenalidomide for multiple myeloma, rituximab for Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and filgrastim for febrile neutropenia.
